Weekly Cardiology Research Analysis
This week’s cardiology literature is highlighted by three high-impact advances: a phase 3 Lancet trial showing large ambulatory BP reductions with the aldosterone synthase inhibitor baxdrostat in resistant hypertension; a NEJM phase 3 trial extending finerenone’s albuminuria-lowering signal to adults with type 1 diabetes and CKD; and a translational CRISPRa study that restores KLF15 activity in cardiomyocytes to reverse pathological gene programs and reduce fibrosis, offering a gene-regulatory t
Summary
This week’s cardiology literature is highlighted by three high-impact advances: a phase 3 Lancet trial showing large ambulatory BP reductions with the aldosterone synthase inhibitor baxdrostat in resistant hypertension; a NEJM phase 3 trial extending finerenone’s albuminuria-lowering signal to adults with type 1 diabetes and CKD; and a translational CRISPRa study that restores KLF15 activity in cardiomyocytes to reverse pathological gene programs and reduce fibrosis, offering a gene-regulatory therapeutic blueprint. Together these studies advance medical therapies (small molecules and gene-regulatory tools), sharpen risk stratification paradigms, and emphasize translational paths from mechanism to clinic.
Selected Articles
1. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
In an international, multicenter phase 3 RCT in patients with resistant hypertension, oral baxdrostat 2 mg daily produced a placebo-corrected reduction in 24-hour ambulatory systolic BP of −14.0 mm Hg at 12 weeks (least-squares mean change −16.6 mm Hg vs −2.6 mm Hg). Adverse events were more frequent with baxdrostat and hyperkalemia >6 mmol/L occurred in 3% of recipients; overall safety was manageable in the short term.
Impact: A rigorous phase 3, double-blind RCT demonstrating a substantial ambulatory BP reduction for a first-in-class aldosterone synthase inhibitor addresses a major unmet need in resistant hypertension and may change add-on therapy options.
Clinical Implications: Baxdrostat could become an effective add-on for patients with resistant hypertension; clinicians should consider ambulatory BP monitoring to assess response and monitor serum potassium closely. Longer-term cardiovascular outcomes and comparative studies versus MR antagonists are needed.
Key Findings
- Placebo-corrected 24-hour ambulatory SBP reduction −14.0 mm Hg (95% CI −17.2 to −10.8) at 12 weeks.
- Least-squares mean change: −16.6 mm Hg (baxdrostat) vs −2.6 mm Hg (placebo).
- Adverse events: 52% with baxdrostat vs 37% with placebo; confirmed K+ >6 mmol/L in 3% vs 0%.
2. Finerenone in Type 1 Diabetes and Chronic Kidney Disease.
In a randomized phase 3 trial of adults with type 1 diabetes and CKD (n=242), finerenone lowered urinary albumin-to-creatinine ratio by 34% at 6 months versus 12% with placebo, corresponding to a 25% greater reduction (geometric mean ratio 0.75; P<0.001). Hyperkalemia was more frequent (10.1% vs 3.3%) and led to few discontinuations; hard renal and cardiovascular outcomes were not assessed in this short-term surrogate endpoint trial.
Impact: Provides the first phase 3 randomized evidence of finerenone’s albuminuria-lowering effect in type 1 diabetes with CKD, expanding the drug’s cardiorenal footprint beyond type 2 diabetes and informing management of a previously under-studied population.
Clinical Implications: Finerenone may be considered to reduce albuminuria in selected T1D-CKD patients with potassium monitoring; clinicians should await longer-term outcome data before broad guideline adoption and consider strategies to mitigate hyperkalemia.
Key Findings
- UACR decreased 34% with finerenone vs 12% with placebo over 6 months; finerenone vs placebo geometric mean ratio 0.75 (95% CI 0.65–0.87; P<0.001).
- Hyperkalemia occurred in 10.1% with finerenone vs 3.3% with placebo; 1.7% discontinued due to hyperkalemia.
- Randomized 242 adults; surrogate endpoint (albuminuria) used over a 6-month follow-up.
3. Enhancing KLF15 activity in cardiomyocytes: a novel approach to prevent pathological reprogramming and fibrosis via nuclease-deficient dCas9VPR.
Using single-cell network analyses, the study identifies reduced KLF15 transcriptional activity as central to pathological cardiomyocytes and demonstrates that AAV-delivered CRISPRa (dCas9VPR) restoring KLF15 suppresses fetal gene reprogramming, normalizes metabolism, and elicits anti-fibrotic cardiomyocyte–fibroblast crosstalk (via AZGP1). A compact AAV-CRISPRa system was engineered to enhance translational potential.
Impact: Presents a first-in-class gene-regulatory therapeutic blueprint for non-genetic heart failure by restoring a disrupted transcriptional hub (KLF15) and demonstrating cell-nonautonomous antifibrotic effects, bridging multi-omic discovery and a translatable delivery platform.
Clinical Implications: Although preclinical, this work nominates KLF15 as a tractable therapeutic hub to reverse maladaptive remodeling and supports early-phase development of cardiomyocyte-targeted CRISPRa or alternative KLF15-activating strategies (small molecules, RNA therapeutics).
Key Findings
- Single-cell network analysis identified reduced KLF15 activity as key in pathological cardiomyocytes.
- CRISPRa (dCas9VPR)–mediated KLF15 enhancement suppressed fetal gene reprogramming, restored metabolic homeostasis, and reduced profibrotic signaling.
- Cardiomyocyte–fibroblast anti-fibrotic crosstalk was mediated via KLF15-dependent AZGP1; a compact AAV-CRISPRa system suitable for translational testing was developed.